摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-Amino-4,7-dihydro-5H-thieno<2,3-c>thiopyran-3-carboxamide | 173281-09-9

中文名称
——
中文别名
——
英文名称
2-Amino-4,7-dihydro-5H-thieno<2,3-c>thiopyran-3-carboxamide
英文别名
2-amino-5,7-dihydro-4H-thieno[2,3-c]thiopyran-3-carboxamide
2-Amino-4,7-dihydro-5H-thieno<2,3-c>thiopyran-3-carboxamide化学式
CAS
173281-09-9
化学式
C8H10N2OS2
mdl
——
分子量
214.312
InChiKey
TWFFCINLEDOZIR-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    387.7±42.0 °C(Predicted)
  • 密度:
    1.465±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.2
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    123
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Synthesis of new fused heterocycles by annelation of thiopyrano[4?,3?:4,5]thieno[2,3-c]pyrimidines
    摘要:
    Appropriately substituted thieno[2,3-c] thiopyrans (2, 3, 5, 6, 10, 11) were converted into 1,5,6,8-tetrahydro-2H-thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-ones (4, 7, 12). These in turn were used as key intermediates for annelations of thiazolo and 1,3-thiazino moieties to yield the tetracyclic target structures 7, 8, 9, and 13, derived from two novel heterocyclic ring systems.
    DOI:
    10.1007/bf00811015
  • 作为产物:
    描述:
    四氢噻喃-4-酮氰乙酰胺吗啉 、 sulfur 作用下, 以 乙醇 为溶剂, 反应 1.0h, 以70%的产率得到2-Amino-4,7-dihydro-5H-thieno<2,3-c>thiopyran-3-carboxamide
    参考文献:
    名称:
    Synthesis of new fused heterocycles by annelation of thiopyrano[4?,3?:4,5]thieno[2,3-c]pyrimidines
    摘要:
    Appropriately substituted thieno[2,3-c] thiopyrans (2, 3, 5, 6, 10, 11) were converted into 1,5,6,8-tetrahydro-2H-thiopyrano[4',3':4,5]thieno[2,3-d]pyrimidin-4(3H)-ones (4, 7, 12). These in turn were used as key intermediates for annelations of thiazolo and 1,3-thiazino moieties to yield the tetracyclic target structures 7, 8, 9, and 13, derived from two novel heterocyclic ring systems.
    DOI:
    10.1007/bf00811015
点击查看最新优质反应信息

文献信息

  • Heterobicyclic Compounds as Pharmaceutically Active Agents
    申请人:Koul Anil
    公开号:US20070275962A1
    公开(公告)日:2007-11-29
    Described are heterobicyclic compounds such as 4,5,6,7-tetrahydrobenzo[b]thiophene-3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]thiopyran 3-carboxylic acid amides, 4,7-dihydro-5H-thieno[2,3-c]pyran-3-carboxylic acid amides, or benzo[b]thiophene-3-carboxylic acid amides and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of various diseases such as infectious diseases, including mycobacteriainduced infections and opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, as well as compositions containing at least one heterobicyclic compound and/or pharmaceutically acceptable salts thereof. Furthermore, reaction procedures for the synthesis of the heterobicyclic compound are disclosed.
    本文介绍了异杂双环化合物,例如4,5,6,7-四氢苯并[b]噻吩-3-羧酸酰胺,4,7-二氢-5H-噻吩[2,3-c]喃-3-羧酸酰胺,4,7-二氢-5H-噻吩[2,3-c]喃-3-羧酸酰胺,或苯并[b]噻吩-3-羧酸酰胺及其药学上可接受的盐。这些衍生物的用途包括预防和/或治疗各种疾病,如传染性疾病,包括分支杆菌感染和机会性疾病,朊病,免疫性疾病,自身免疫性疾病,双相和临床障碍,心血管疾病,细胞增殖性疾病,糖尿病,炎症,移植排斥,勃起功能障碍,神经退行性疾病和中风,以及含有至少一种异杂双环化合物和/或药学上可接受的盐的组合物。此外,还公开了合成异杂双环化合物的反应程序。
  • Novel therapeutic targets for the treatment of mycobacterial infections and compounds useful therefor
    申请人:——
    公开号:US20040171603A1
    公开(公告)日:2004-09-02
    Described herein is the discovery that certain mycobacterial serine/threonine protein kinases, particularly protein kinase G (PknG), are effective therapeutic targets for the treatment of mycobacterial infections. Furthermore, the present application refers to the use of mycobacterial serine/threonine protein kinases for developing methods for detection and determination of these kinases for recognizing and monitoring diseases and for controlling therapy of diseases. Additionally disclosed are novel 4,5,6,7-tetrahydrobenzo[b]thiophene compounds, benzo(g)quinoxaline compounds, and pharmaceutically acceptable salts thereof, and methods of using such compounds and salts thereof for the prophylaxis and/or treatment of virally and/or bacterially induced infections, particularly mycobacteria-induced infections, including opportunistic infections, as well as pharmaceutical compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene compound and/or benzo(g)quinoxaline compound and/or pharmaceutically acceptable salts thereof in a pharmaceutically acceptable carrier.
    本文描述的是发现某些分枝杆菌丝氨酸/苏酸蛋白激酶,特别是蛋白激酶 G (PknG),是治疗分枝杆菌感染的有效治疗靶点。此外,本申请还涉及利用分枝杆菌丝氨酸/苏酸蛋白激酶开发检测和测定这些激酶的方法,用于识别和监测疾病以及控制疾病的治疗。此外,还公开了新型 4,5,6,7-四氢苯并[b]噻吩化合物、苯并(g)喹喔啉化合物及其药学上可接受的盐,以及使用此类化合物及其盐预防和/或治疗病毒和/或细菌引起的感染,特别是分枝杆菌引起的感染(包括机会性感染)的方法,以及含有至少一种 4,5,6,7-四氢苯并&lsqb;b]噻吩化合物和/或苯并(g)喹喔啉化合物和/或其药学上可接受的盐,并将其置于药学上可接受的载体中。
  • 4,5,6,7-TRETRAHYDROBENZO(B) THIOPHENE DERIVATIVES AND METHODS FOR MEDICAL INTERVENTION AGAINST MYCROBACTERIAL INFECTIONS
    申请人:Axxima Pharmaceuticals AG
    公开号:EP1492783A1
    公开(公告)日:2005-01-05
  • HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS
    申请人:GPC Biotech AG
    公开号:EP1670804A2
    公开(公告)日:2006-06-21
  • 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and methods for medical intervention against mycobacterial infections
    申请人:Missio Andrea
    公开号:US20090018149A1
    公开(公告)日:2009-01-15
    Described are 4,5,6,7-tetrahydrobenzo[b]thiophene derivatives and pharmaceutically acceptable salts thereof, the use of these derivatives for the prophylaxis and/or treatment of mycobacteria-induced infections and opportunistic infections, as well as compositions containing at least one 4,5,6,7-tetrahydrobenzo[b]thiophene derivative and/or pharmaceutically acceptable salts thereof. Furthermore, the present application refers to the use of mycobacterial protein serine/threonine kinases for developing methods for detection and determination of these kinases for recognising and monitoring diseases and for controlling therapy of diseases.
查看更多

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (双(2,2,2-三氯乙基)) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-氨氯地平-d4 (S)-8-氟苯并二氢吡喃-4-胺 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯 (R,S)-可替宁N-氧化物-甲基-d3 (R,S)-六氢-3H-1,2,3-苯并噻唑-2,2-二氧化物-3-羧酸叔丁酯 (R)-(+)-5'-苄氧基卡维地洛 (R)-(+)-2,2'',6,6''-四甲氧基-4,4''-双(二苯基膦基)-3,3''-联吡啶(1,5-环辛二烯)铑(I)四氟硼酸盐 (R)-卡洛芬 (R)-N'-亚硝基尼古丁 (R)-DRF053二盐酸盐 (R)-4-异丙基-2-恶唑烷硫酮 (R)-3-甲基哌啶盐酸盐; (R)-2-苄基哌啶-1-羧酸叔丁酯 (N-(Boc)-2-吲哚基)二甲基硅烷醇钠 (N-{4-[(6-溴-2-氧代-1,3-苯并恶唑-3(2H)-基)磺酰基]苯基}乙酰胺) (E)-2-氰基-3-(5-(2-辛基-7-(4-(对甲苯基)-1,2,3,3a,4,8b-六氢环戊[b]吲哚-7-基)-2H-苯并[d][1,2,3]三唑-4-基)噻吩-2-基)丙烯酸 (E)-2-氰基-3-[5-(2,5-二氯苯基)呋喃-2-基]-N-喹啉-8-基丙-2-烯酰胺 (8α,9S)-(+)-9-氨基-七氢呋喃-6''-醇,值90% (6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 (6-羟基嘧啶-4-基)乙酸 (6,7-二甲氧基-4-(3,4,5-三甲氧基苯基)喹啉) (6,6-二甲基-3-(甲硫基)-1,6-二氢-1,2,4-三嗪-5(2H)-硫酮) (5aS,6R,9S,9aR)-5a,6,7,8,9,9a-六氢-6,11,11-三甲基-2-(2,3,4,5,6-五氟苯基)-6,9-甲基-4H-[1,2,4]三唑[3,4-c][1,4]苯并恶嗪四氟硼酸酯 (5R,Z)-3-(羟基((1R,2S,6S,8aS)-1,3,6-三甲基-2-((E)-prop-1-en-1-yl)-1,2,4a,5,6,7,8,8a-八氢萘-1-基)亚甲基)-5-(羟甲基)-1-甲基吡咯烷-2,4-二酮 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-(4-乙氧基-3-甲基苄基)-1,3-苯并二恶茂) (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氯-2,1,3-苯并噻二唑-4-基)-氨基甲氨基硫代甲酸甲酯一氢碘 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (5-氨基-1,3,4-噻二唑-2-基)甲醇 (4aS-反式)-八氢-1H-吡咯并[3,4-b]吡啶 (4aS,9bR)-6-溴-2,3,4,4a,5,9b-六氢-1H-吡啶并[4,3-B]吲哚 (4S,4''S)-2,2''-环亚丙基双[4-叔丁基-4,5-二氢恶唑] (4-(4-氯苯基)硫代)-10-甲基-7H-benzimidazo(2,1-A)奔驰(德)isoquinolin-7一 (4-苄基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (4-己基-2-甲基-4-nitrodecahydropyrido〔1,2-a][1,4]二氮杂) (4,5-二甲氧基-1,2,3,6-四氢哒嗪)